Population Pharmacokinetics of Dolutegravir in Plasma and Cerebrospinal Fluid in Adults Living With HIV

ABSTRACT Characterizing dolutegravir penetration into the central nervous system is important for optimizing human immunodeficiency virus treatment outcomes, yet population‐specific pharmacokinetic data describing cerebrospinal fluid disposition and equilibration kinetics remain lacking. This study characterizes dolutegravir pharmacokinetics in plasma and cerebrospinal fluid to describe the plasma‐to‐cerebrospinal fluid equilibration rate constant and cerebrospinal fluid‐to‐plasma pseudo‐partition coefficient. Sparse pharmacokinetics samples were collected from 121 antiretroviral therapy‐experienced adults who are predominantly overweight or obese (body mass index: 32.2 ± 8.7 kg/m 2 ) receiving daily dolutegravir (50 mg)‐based therapy. The model was developed using nonlinear mixed‐effects modeling in NONMEM. Plasma dolutegravir pharmacokinetics were best described by a one‐compartment model with first‐order absorption and elimination. The population estimate for apparent oral clearance was 1.38 L/h/70 kg. Cerebrospinal fluid data were modeled using a sequential approach with a hypothetical effect compartment linked to plasma to estimate equilibration kinetics and relative cerebrospinal fluid exposure at steady‐state. Key cerebrospinal fluid penetration parameters included a plasma‐to‐cerebrospinal fluid equilibration rate constant of 0.38 h −1 , corresponding to an equilibration half‐life of 1.82 h, and a cerebrospinal fluid‐to‐plasma pseudo‐partition coefficient of 0.0015, indicating 0.15% cerebrospinal fluid penetration relative to plasma. Post hoc estimated area under the concentration‐time curve (0–24) demonstrated a moderate inverse correlation with body mass index ( r = −0.34), indicating that dolutegravir exposure decreases with increasing body mass index. The model revealed rapid plasma‐to‐cerebrospinal fluid equilibration kinetics with low steady‐state cerebrospinal fluid penetration in this predominantly overweight and obese population.

Authors

Institutions

Publication Details

Journal
CPT Pharmacometrics & Systems Pharmacology
Published
2026-09-29
DOI
https://doi.org/10.1002/psp4.70345
Primary Topic
HIV/AIDS drug development and treatment
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
article

Population Pharmacokinetics of Dolutegravir in Plasma and Cerebrospinal Fluid in Adults Living With HIV

Alan Winston, Ahmed Aliyu Abulfathi, Joseph Frank Standing, Eric H. Decloedt et al.
CPT Pharmacometrics & Systems Pharmacology
HIV/AIDS drug development and treatment
article

Population Pharmacokinetics of Dolutegravir in Plasma and Cerebrospinal Fluid in Adults Living With HIV

Alan Winston, Ahmed Aliyu Abulfathi, Joseph Frank Standing, Eric H. Decloedt, Saye Khoo, John Joska, Mohammed Wulgo Ali, Tracy Kellermann, Sam Nightingale
article en

Abstract

ABSTRACT Characterizing dolutegravir penetration into the central nervous system is important for optimizing human immunodeficiency virus treatment outcomes, yet population‐specific pharmacokinetic data describing cerebrospinal fluid disposition and equilibration kinetics remain lacking. This study characterizes dolutegravir pharmacokinetics in plasma and cerebrospinal fluid to describe the plasma‐to‐cerebrospinal fluid equilibration rate constant and cerebrospinal fluid‐to‐plasma pseudo‐partition coefficient. Sparse pharmacokinetics samples were collected from 121 antiretroviral therapy‐experienced adults who are predominantly overweight or obese (body mass index: 32.2 ± 8.7 kg/m 2 ) receiving daily dolutegravir (50 mg)‐based therapy. The model was developed using nonlinear mixed‐effects modeling in NONMEM. Plasma dolutegravir pharmacokinetics were best described by a one‐compartment model with first‐order absorption and elimination. The population estimate for apparent oral clearance was 1.38 L/h/70 kg. Cerebrospinal fluid data were modeled using a sequential approach with a hypothetical effect compartment linked to plasma to estimate equilibration kinetics and relative cerebrospinal fluid exposure at steady‐state. Key cerebrospinal fluid penetration parameters included a plasma‐to‐cerebrospinal fluid equilibration rate constant of 0.38 h −1 , corresponding to an equilibration half‐life of 1.82 h, and a cerebrospinal fluid‐to‐plasma pseudo‐partition coefficient of 0.0015, indicating 0.15% cerebrospinal fluid penetration relative to plasma. Post hoc estimated area under the concentration‐time curve (0–24) demonstrated a moderate inverse correlation with body mass index ( r = −0.34), indicating that dolutegravir exposure decreases with increasing body mass index. The model revealed rapid plasma‐to‐cerebrospinal fluid equilibration kinetics with low steady‐state cerebrospinal fluid penetration in this predominantly overweight and obese population.

CPT Pharmacometrics & Systems PharmacologyVol. 15(10)
University of Liverpool (GB), Imperial College Healthcare NHS Trust (GB), University of Cape Town (ZA), Stellenbosch University (ZA), Certara (United States) (US), University College London (GB), Gombe State University (NG)
Good health and well-being
Openalex Percentile: Top 12%
HIV/AIDS drug development and treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.